Y-mAbs Therapeutics, Inc.

As of February 25, 2021, Y-mAbs Therapeutics, Inc. is considered a risky investment due to its overvaluation, negative financial metrics, and significant underperformance compared to industry peers and the S&P 500.

As of February 25, 2021, Y-mAbs Therapeutics, Inc. is considered overvalued and classified as risky due to negative financial metrics, including a P/E ratio and a year-to-date return of -39.72%, significantly underperforming the S&P 500.

As of June 20, 2025, Y-mAbs Therapeutics, Inc. shows a bearish trend with moderate strength, supported by mixed signals from MACD and Bollinger Bands, indicating a bearish outlook, especially in the long term.

As of March 2022, the management team of Y-mAbs Therapeutics, Inc. includes Mr. Thomas Gad (Chairman, President, Founder), Dr. Claus Moller-San Pedro (CEO), and Mr. Bo Kruse (CFO). The Board of Directors also features independent members such as Dr. Gerard Ber and Mr. David Gill.

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies, with a market cap of $217.42 million and recent net sales of $21 million. The company reported a net loss of $5 million for the quarter ending March 2025.

As of Jun 18, Y-mAbs Therapeutics, Inc. has a market capitalization of 217.42 million and reported net sales of 88.66 million, with a net profit loss of 28.24 million. Shareholder's funds are at 92.00 million, and total assets are 119.90 million.